NR2C-Selective NMDA Modulators for CNS Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NMDA receptor modulators for treating central nervous system disorders often come with side effects such as sedation and hallucinations, necessitating the development of more effective and safer therapeutic agents.
Innovation Solution
Development of NR2C subunit-selective NMDA receptor potentiators and antagonists, specifically compounds of Formula I and their pharmaceutical compositions, which can be administered alone or in combination with other active agents to treat various central nervous system disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional NMDA receptor modulators are used to treat CNS disorders, then therapeutic effects are achieved, but side effects such as sedation and hallucinations occur
Solution Approach 1:
The patent segments the NMDA receptor system into distinct subunits (NR2A, NR2B, NR2C, NR2D) and develops compounds that selectively target specific subunits. This segmentation allows therapeutic effects to be achieved through selective modulation of particular receptor subtypes while avoiding activation of other subunits that mediate side effects, thus resolving the contradiction between efficacy and safety
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular structures (Formula I compounds containing quinazolinone or quinolinone cores with specific substituents) that exhibit preferential binding to certain NMDA receptor subunits. This localized selectivity ensures that therapeutic actions are concentrated on target receptors while minimizing off-target effects that cause sedation and hallucinations
2Productivity
If NMDA receptor modulators are administered to achieve therapeutic outcomes, then CNS disorder symptoms are treated, but safety and tolerability are compromised
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular parameters of the core compounds (Formula I structures with varying R1, R2, R3 substituents) to optimize the balance between therapeutic efficacy and safety. By adjusting structural parameters, the compounds achieve enhanced selectivity for specific NMDA subunits, improving therapeutic outcomes while maintaining safety and tolerability
Data Source
AI summary
This disclosure relates to NMDA modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are NR2C subunit-selective NMDA potentiators. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiments, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof. In certain embodiments, the disclosure relates to methods of treating or preventing nervous system disorders comprising administering an effective amount of a composition comprising compound disclosed herein to a subject in need thereof.